Pipeline
Non-narcotic Strong Analgesic (TRPV1 Antagonist)
Severe pain is an unbearable thing of mankind
Non-narcotic Strong Analgesic (TRPV1 Antagonist)
Neuropathic pain is a chronic severe pain caused by damage to the nervous system due to diseases or accidents. So far, the most effective remedy for this disease is a narcotic analgesic drug as like morphine. The serious side effect of morphine is addiction.
TRPV1 Antagonist is more effective than conventional nonsteroidal antiinflammatory agents (aspirin, ibuprofen, etc.) and Tylenol. TRPV1 antagonist is not only less side effect than narcotic analgesics but also has comparable efficacy to narcotic analgesics.
TRPV1 Antagonist is more effective than conventional nonsteroidal antiinflammatory agents (aspirin, ibuprofen, etc.) and Tylenol. TRPV1 antagonist is not only less side effect than narcotic analgesics but also has comparable efficacy to narcotic analgesics.
Competitor
Pfizer pre-clinical
Indications
Postherpetic neuralgia
Diabetic neuropathy
Cancer pain
CRPS
Fibromyalgia
Diabetic neuropathy
Cancer pain
CRPS
Fibromyalgia
Research & Development
“ First In Class ”
2005
Agreement for out-license and joint development with Grünenthal (Germany): total deal package 40 million Euro
2007
Showed hyperthermia
2009
~
2015
~
2015
Non-clinical trial succeeded with non human primates
- Solve the hyperthermia problem completely
- Prove efficacy in non human primates
- Solve the hyperthermia problem completely
- Prove efficacy in non human primates
2017
EMA Preparing Phase 1 clinical trial
Neuropathic pain analgesics (TRPV1 agonist, topical cream/gel or patch)
New generation of analgesics from TRPV1 agonist not like antagonist
Competitor
ENDO pharmaceuticals Lidoderm®
Astellas Europe ®
Purdue Pharma opioid patch®
Astellas Europe ®
Purdue Pharma opioid patch®
Indications
Postherpetic neuralgia
Diabetic neuropathy
Neuropathic back pain
Diabetic neuropathy
Neuropathic back pain
Research & Development
Clinical candidate selection
MDR-652
Negotiation on going to make partnership with domestic and foreign pharmaceutical companies
Developing disease modifying drugs for Alzheimer's disease (AD)
AD Drug Development Strategy
AD drug development (anti-oligomerization of beta-amyloid)
Mechanism to prevent brain neuronal cell death by blocking aggregation of Αβ in brain
Competitor
Global pharmaceutical company such as Elan, Allon
Research & Development
2008
Joint development contract with Daewoong pharma
2011
GLP toxicity study completed
2015
Phase 1 human clinical trial SAD completed
2017
Negotiation with Global Clinical Partner
AD drug development (RAGE modulator)
Inhibition of interaction Αβ and RAGE(Receptor for Advanced Glycation Endproduct) that can block Αβ influx into brain from plasma
Competitor
Global pharmaceutical company Pfizer
(vTv Therapeutics)
(vTv Therapeutics)
Research & Development
2010
Out-license deal with Roche, a multinational pharmaceutical company
(total package $ 290 million)
(total package $ 290 million)
2017
Efficacy test in animal study
AD DRUG Development status
❶ α-Secretase activator
❷ β-Secretase Inhibitor
❸ γ-Secretase Inhibitor
❷ β-Secretase Inhibitor
❸ γ-Secretase Inhibitor
Big Pharma has developed ❶and❸ expensing $ 200 to $ 300 million for each company over the past decade, but failed to overcome the side effects Merck, Astellas developing ❷BACE1 Inhibitor
❹ aggregation Inhibitor
A solution that minimizes side effects
Big Pharma's interest in aggregation Inhibitor
Only 6 to 7 bio-ventures developed aggregation Inhibitor worldwide
Big Pharma's interest in aggregation Inhibitor
Only 6 to 7 bio-ventures developed aggregation Inhibitor worldwide
❺ RAGE antagonist
Worldwide Pfizer and Medifron (Roche) developed RAGE modulator only
Preventing Αβ protein from entering the brain
(preventive and therapeutic effects)
(preventive and therapeutic effects)
❻ Αβ antibodies
Johnson & Johnson, Lilly, Pfizer Phase Ⅲ failed clinical trial with antibody therapeutics
Roche gantenerumab phase Ⅲ failed
Roche crenezumab prevention therapy on going
Roche gantenerumab phase Ⅲ failed
Roche crenezumab prevention therapy on going
❼ QC Inhibitor
Probiodrug (Germany) phase Ⅱ trial on going
Aβ and tau protein pathway block
Aβ and tau protein pathway block
❽ LMTX
Tau protein hyperphosphorylation inhibitor
TauRX(Singapore) phase Ⅲ failed
TauRX(Singapore) phase Ⅲ failed
❾ O-GlcNAc Inhibitor
Merck & Co. pre-clinical stage
Tau Hyperphosphorylation inhibitor
Tau Hyperphosphorylation inhibitor
Development of AD Early Diagnosis Kit
Methods for diagnosing AD include cognitive testing mini-mental state examination (MMSE), Magnetic resonance imaging (MRI), positron emission tomography (PET), and spinal fluid examination.
MMSE has the disadvantage of poor accuracy and other methods have high accuracy but high cost. Our AD diagnostic Kit has a relatively high level of accuracy at a low cost. Now we are focused on upgrading for more accurate diagnostic efficacy.
MMSE has the disadvantage of poor accuracy and other methods have high accuracy but high cost. Our AD diagnostic Kit has a relatively high level of accuracy at a low cost. Now we are focused on upgrading for more accurate diagnostic efficacy.
Competitor
The world's first Alzheimer's Disease Early Diagnosis Kit using human blood sample
Research & Development
2015
KFDA license for export
2017
Clinical Validation is underway for the approval of domestic products